➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Johnson and Johnson
Dow
Harvard Business School
Baxter
Moodys

Last Updated: October 19, 2020

DrugPatentWatch Database Preview

Lusutrombopag - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for lusutrombopag and what is the scope of patent protection?

Lusutrombopag is the generic ingredient in one branded drug marketed by Shionogi Inc and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Lusutrombopag has fifty-three patent family members in eighteen countries.

One supplier is listed for this compound.

Summary for lusutrombopag
International Patents:53
US Patents:4
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 22
Clinical Trials: 1
Patent Applications: 8
DailyMed Link:lusutrombopag at DailyMed
Recent Clinical Trials for lusutrombopag

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
ShionogiPhase 3

See all lusutrombopag clinical trials

US Patents and Regulatory Information for lusutrombopag

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Shionogi Inc MULPLETA lusutrombopag TABLET;ORAL 210923-001 Jul 31, 2018 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Shionogi Inc MULPLETA lusutrombopag TABLET;ORAL 210923-001 Jul 31, 2018 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Shionogi Inc MULPLETA lusutrombopag TABLET;ORAL 210923-001 Jul 31, 2018 RX Yes Yes   Start Trial   Start Trial   Start Trial
Shionogi Inc MULPLETA lusutrombopag TABLET;ORAL 210923-001 Jul 31, 2018 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Shionogi Inc MULPLETA lusutrombopag TABLET;ORAL 210923-001 Jul 31, 2018 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for lusutrombopag

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2184279 CR 2019 00038 Denmark   Start Trial PRODUCT NAME: LUSUTROMBOPAG OG FARMACEUTISK ACCEPTABLE SALTE ELLER SOLVATER DERAF; REG. NO/DATE: EU/1/18/1348 20190220
2184279 19C1043 France   Start Trial PRODUCT NAME: LUSUTROMBOPAG, UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI OU UN SOLVATE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/18/1348 20190220
2184279 300998 Netherlands   Start Trial PRODUCT NAME: LUSUTROMBOPAG OF FARMACEUTISCH AANVAARDBARE ZOUTEN OF SOLVATEN DAARVAN; REGISTRATION NO/DATE: EU/1/18/1348 20190220
2184279 CA 2019 00038 Denmark   Start Trial PRODUCT NAME: LUSUTROMBOPAG OG FARMACEUTISK ACCEPTABLE SALTE ELLER SOLVATER DERAF; REG. NO/DATE: EU/1/18/1348 20190220
2184279 C201930048 Spain   Start Trial PRODUCT NAME: LUSUTROMBOPAG; NATIONAL AUTHORISATION NUMBER: EU/01/18/1348; DATE OF AUTHORISATION: 20190218; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/01/18/1348; DATE OF FIRST AUTHORISATION IN EEA: 20190218
2184279 132019000000090 Italy   Start Trial PRODUCT NAME: LUSUTROMBOPAG(LUSUTROMBOPAG SHIONOGI); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/18/1348, 20190220
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Colorcon
Baxter
Dow
Moodys
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.